Clinical stage immuno-oncology company focused on novel applications of liposome constructs to disrupt existing immuno-oncology technologies. The company's lead clinical development program is HF1K16, a drug encapsulated immune modulating liposome of all-trans retinoic acid targeting myeloid-derived suppressor cells for treatment of solid tumor cancers.
Additional programs include immunoliposomes designed to improve efficacy and toxicity of existing of existing immuno-oncology technologies including ADCs and CAR-T.
Company Details
- Employees
- 3
- Address
- Hangzhou, Cn
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Markina-Xemein.
- HQ
- Hangzhou
Highfield Biopharmaceuticals Questions
Highfield Biopharmaceuticals's LinkedIn profile is https://cn.linkedin.com/company/highfield-biopharma
Highfield Biopharmaceuticals has
3 employees.
View email and phone details for 3
employees at Highfield Biopharmaceuticals.
Highfield Biopharmaceuticals's industry is
Biotechnology Research
Highfield Biopharmaceuticals's top competitors are
Atom Therapeutics,
Biocentury Inc.,
Unchained Labs,
Bioatla, Inc.,
Cayuga Biotech,
Ona Therapeutics,
Leartiker,
Arnav Biotech,
Pharmavolution,
Hightide Therapeutics.
Highfield Biopharmaceuticals's categories are Biotechnology Research
